You have 5 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD-30 CART

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hodgkin Lymphoma, Adult, Hodgkin Disease Recurrent, Hodgkin Disease Refractory Trial in United States (CD30.CAR-T, Fludarabine,

Active, not recruiting
  • Hodgkin Lymphoma, Adult
  • +3 more
  • Duarte, California
  • +4 more
Apr 3, 2022

DLBCL, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial (biological, procedure, drug,

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • +6 more
  • Axicabtagene Ciloleucel
  • +10 more
  • (no location specified)
Jan 13, 2023

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma Refractory, Non-Hodgkin's Lymphoma, Relapsed

Recruiting
  • Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • Autologous CAR19 T lymphocytes
  • Prague, Czechia
    Institute of Hematology and Blood Transfusion, Czech Republic
Aug 3, 2022

Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma Trial (PACE CART19)

Withdrawn
  • Acute Lymphoblastic Leukemia
  • +2 more
  • PACE CART19
  • (no location specified)
Mar 9, 2022

B-Cell Non-Hodgkin Lymphoma, DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma Trial in Seattle (Acalabrutinib,

Recruiting
  • B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Dec 9, 2022

Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Classical Hodgkin Lymphoma Trial in Houston (CD30.CAR-EBVST cells)

Recruiting
  • Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
  • Classical Hodgkin Lymphoma
  • CD30.CAR-EBVST cells
  • Houston, Texas
  • +1 more
Jul 20, 2022

Lymphoma, Relapse/Recurrence Trial in Wuhan, Nanchang (CD30 CAR-T, Camrelizumab)

Recruiting
  • Lymphoma
  • Relapse/Recurrence
  • Wuhan, Hubei, China
  • +1 more
Apr 8, 2022

T Cell Lymphoma Trial in Kansas City (Brentuximab Vedotin)

Withdrawn
  • T Cell Lymphoma
  • Brentuximab Vedotin
  • Kansas City, Kansas
    The University of Kansas Cancer Center, Westwood Campus
Feb 1, 2023

B Cell Leukemias, B Cell Lymphomas Trial in Philadelphia (CART22 cells transduced with a lentiviral vector to express anti-CD22

Recruiting
  • B Cell Leukemias
  • B Cell Lymphomas
  • CART22 cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB
  • Philadelphia, Pennsylvania
    Children's Hospital of Philadelphia
Jan 19, 2022

Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Seattle (drug, other,

Recruiting
  • Recurrent Hodgkin Lymphoma
  • +3 more
  • Brentuximab Vedotin
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 4, 2022

Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma, Extranodal NK/T-cell Lymphoma Trial in Duarte, Nashville, Houston

Active, not recruiting
  • Anaplastic Large Cell Lymphoma
  • +4 more
  • Duarte, California
  • +3 more
Jul 21, 2022

Chemo Resistant Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia Trial in Philadelphia (CART22-65s cells,

Active, not recruiting
  • Chemotherapy Resistant Acute Lymphoblastic Leukemia
  • Refractory Acute Lymphoblastic Leukemia
  • CART22-65s cells
  • huCART19 Cells
  • Philadelphia, Pennsylvania
    University of Pennsylvania
Feb 18, 2022

Peripheral T Cell Lymphoma Trial in Chapel Hill, Winston-Salem (ATLCAR.CD30 T cells, Bendamustine, Fludarabine)

Recruiting
  • Peripheral T Cell Lymphoma
  • ATLCAR.CD30 T cells
  • +3 more
  • Chapel Hill, North Carolina
  • +1 more
Mar 4, 2022

Leukemia, T Cell Trial in Beijing (CD7 CART)

Recruiting
  • Leukemia, T Cell
  • CD7 CART
  • Beijing, Hebei, China
    He bei Yan da Lu dao pei Hospital
May 24, 2022

A Study of People With CD30 Positive Lymphoma in China

Not yet recruiting
  • Lymphoma
    • (no location specified)
    Aug 17, 2022

    Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma Trial (AFM13, AB-101, Cyclophosphamide)

    Not yet recruiting
    • Relapsed or Refractory Hodgkin Lymphoma
    • Peripheral T Cell Lymphoma
    • (no location specified)
    May 30, 2023

    T-Cell Lymphoma Trial (Brentuximab vedotin)

    Not yet recruiting
    • T-Cell Lymphoma
    • Brentuximab vedotin
    • (no location specified)
    Jun 30, 2022

    Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Suzhou (CD19/22 CART, Tislelizumab)

    Unknown status
    • Relapsed Non Hodgkin Lymphoma
    • Refractory Non-Hodgkin Lymphoma
    • Suzhou, Jiangsu, China
      The First Affiliated Hospital of Soochow University
    Jul 30, 2021

    Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL, Infants With Very High Risk KMT2A B-ALL, Patients With CNS

    Active, not recruiting
    • Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL
    • +2 more
    • Murine CART19
    • Philadelphia, Pennsylvania
      Children's Hospital of Philadelphia
    Jan 11, 2022

    Melanoma (Skin) Trial in Cologne (MB-CART20.1)

    Recruiting
    • Melanoma (Skin)
    • MB-CART20.1
    • Cologne, NRW, Germany
      University Hospital of Cologne - Clinic for Internal Medicine I
    Sep 20, 2021

    Lymphoma Trial in China (Brentuximab Vedotin, Cyclophosphamide, Doxorubicin)

    Not yet recruiting
    • Lymphoma
    • Brentuximab Vedotin
    • +3 more
    • Beijing, China
    • +15 more
    Jan 4, 2023

    Brentuximab Vedotin Intravenous Infusion "Untreated

    Active, not recruiting
    • Untreated CD30-Positive Hodgkin's Lymphoma
    • Brentuximab vedotin (Genetical Recombination)
    • Tokyo, Japan
      Takeda Selected Site
    Mar 24, 2022

    Hodgkin Lymphoma Trial in Valhalla (Brentuximab Vedotin, Allogeneic Stem Cell Transplantation, Reduced Intensity Conditioning)

    Active, not recruiting
    • Hodgkin Lymphoma
    • Brentuximab Vedotin
    • +2 more
    • Valhalla, New York
      New York Medical College
    Oct 24, 2022

    Safety and Efficacy Trial in Suzhou (anti-CD19 and anti-BCMA CAR, Immunomodulatory drugs)

    Recruiting
    • Safety and Efficacy
    • anti-CD19 and anti-BCMA CAR
    • Immunomodulatory drugs
    • Suzhou, Jiangsu, China
      First Affiliated Hospital, Soochow University
    May 17, 2021

    Classical Hodgkin Lymphoma, Hodgkin Disease Refractory, Hodgkin Disease Recurrent Trial in United States (Nivolumab, Autologous

    Recruiting
    • Classical Hodgkin Lymphoma
    • +2 more
    • Duarte, California
    • +4 more
    Jun 27, 2022